Jiang Zhong Pharmaceutical (SHA:600750) recorded an attributable profit of 784.9 million yuan in 2024, up 9.2% from 718.7 million yuan in 2023.
The Chinese drugmaker's basic earnings per share stood at 1.25 yuan in 2024, up from 1.14 yuan in 2023.
Total operating revenue fell 2.6% to 4.44 billion yuan from 4.55 billion yuan a year prior, according to a Jan. 24 bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。